Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC00552 (long intergenic non-protein coding RNA 552) is a long non-coding RNA (lncRNA) gene located on chromosome 13 (13q34, reverse strand)[3][5]. Unlike protein-coding genes, it does not encode a protein but instead produces a transcript that participates in regulating gene expression and various cellular processes[1][3]. LINC00552 has been implicated in the regulation of cell proliferation, apoptosis, and migration[1]. Emerging evidence suggests that LINC00552 may play roles in cancer biology: altered expression has been observed in several cancers, notably breast cancer, where it can be associated with either tumor suppression or oncogenic activity depending on context and molecular subtype. It appears to influence cancer cell growth, DNA damage response, and cell cycle regulation, potentially acting as a "sponge" for microRNAs that modulate signaling pathways[2]. There are no drugs known to directly target LINC00552, and its use as a clinical biomarker or therapeutic target remains investigational[2].
Not applicable (as direct drug target is unknown)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on long intergenic non-protein coding RNA 552 (LINC00552).